Can an antiviral drug stop RSV in vulnerable patients?
NCT ID NCT06817889
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the antiviral drug remdesivir can help treat RSV (a common respiratory virus) in people whose immune systems are weakened by certain cancer treatments or autoimmune therapies. About 60 adults with confirmed RSV will receive remdesivir intravenously. The main goal is to see if it reduces the need for extra oxygen, which would indicate less severe lung infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
remdesivir
What this could lead to
If it works, this could provide a treatment option for RSV in people with weakened immune systems, potentially preventing serious lung infections.
What could go wrong
This is an early phase 2 trial with only 60 participants, so results may not apply broadly. Remdesivir may not reduce oxygen needs, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Comprehensive Cancer Center
NOT_YET_RECRUITINGDuarte, California, 91010, United States
Contact
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact